Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807.

Literature DB >> 23234879

Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807.

David T Chien¹, Shadfar Bahri, A Katrin Szardenings, Joseph C Walsh, Fanrong Mu, Min-Ying Su, William R Shankle, Arkadij Elizarov, Hartmuth C Kolb.

Abstract

Aggregates of hyperphosphorylated tau (PHF-tau), such as neurofibrillary tangles, are linked to the degree of cognitive impairment in Alzheimer's disease. We have developed a novel PHF-tau targeting positron emission tomography imaging agent, [F-18]-T807, which may be useful for imaging Alzheimer's disease and other tauopathies. Here in, we describe the first human brain images with [F-18]-T807.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2013 PMID： 23234879 DOI： 10.3233/JAD-122059

Source DB: PubMed Journal: J Alzheimers Dis ISSN： 1387-2877 Impact factor: 4.472

Keyword Cloud
Cited

296 in total

Review 1. Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau.

Authors: Keith A Josephs
Journal: Mayo Clin Proc Date: 2017-08 Impact factor: 7.616

2. The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.

Authors: E Cavedo; S Lista; Z Khachaturian; P Aisen; P Amouyel; K Herholz; C R Jack; R Sperling; J Cummings; K Blennow; S O'Bryant; G B Frisoni; A Khachaturian; M Kivipelto; W Klunk; K Broich; S Andrieu; M Thiebaut de Schotten; J-F Mangin; A A Lammertsma; K Johnson; S Teipel; A Drzezga; A Bokde; O Colliot; H Bakardjian; H Zetterberg; B Dubois; B Vellas; L S Schneider; H Hampel
Journal: J Prev Alzheimers Dis Date: 2014-12

Review 3. Suspected non-Alzheimer disease pathophysiology--concept and controversy.

Authors: Clifford R Jack; David S Knopman; Gaël Chételat; Dennis Dickson; Anne M Fagan; Giovanni B Frisoni; William Jagust; Elizabeth C Mormino; Ronald C Petersen; Reisa A Sperling; Wiesje M van der Flier; Victor L Villemagne; Pieter J Visser; Stephanie J B Vos
Journal: Nat Rev Neurol Date: 2016-01-18 Impact factor: 42.937

4. Characterization of the radiolabeled metabolite of tau PET tracer ¹⁸F-THK5351.

Authors: Ryuichi Harada; Shozo Furumoto; Tetsuro Tago; Katsutoshi Furukawa; Aiko Ishiki; Naoki Tomita; Ren Iwata; Manabu Tashiro; Hiroyuki Arai; Kazuhiko Yanai; Yukitsuka Kudo; Nobuyuki Okamura
Journal: Eur J Nucl Med Mol Imaging Date: 2016-07-19 Impact factor: 9.236

5. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies.

Authors: Maiko Ono; Naruhiko Sahara; Katsushi Kumata; Bin Ji; Ruiqing Ni; Shunsuke Koga; Dennis W Dickson; John Q Trojanowski; Virginia M-Y Lee; Mari Yoshida; Isao Hozumi; Yasumasa Yoshiyama; John C van Swieten; Agneta Nordberg; Tetsuya Suhara; Ming-Rong Zhang; Makoto Higuchi
Journal: Brain Date: 2017-03-01 Impact factor: 13.501

Review 6. Multimodality Review of Amyloid-related Diseases of the Central Nervous System.

Authors: Michelle M Miller-Thomas; Adam L Sipe; Tammie L S Benzinger; Jonathan McConathy; Sarah Connolly; Katherine E Schwetye
Journal: Radiographics Date: 2016 Jul-Aug Impact factor: 5.333

Review 7. Tau immunotherapy and imaging.

Authors: Einar M Sigurdsson
Journal: Neurodegener Dis Date: 2013-09-11 Impact factor: 2.977

Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807.

Review 1. Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau.

2. The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.

Review 3. Suspected non-Alzheimer disease pathophysiology--concept and controversy.

4. Characterization of the radiolabeled metabolite of tau PET tracer ¹⁸F-THK5351.

5. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies.

Review 6. Multimodality Review of Amyloid-related Diseases of the Central Nervous System.

Review 7. Tau immunotherapy and imaging.

Review 8. Biomarker modelling of early molecular changes in Alzheimer's disease.

9. Pharmacokinetic Evaluation of the Tau PET Radiotracer ¹⁸F-T807 (¹⁸F-AV-1451) in Human Subjects.

Review 10. Interactions between Microtubule-Associated Protein Tau (MAPT) and Small Molecules.

Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807.

Review 1. Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau.

2. The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.

Review 3. Suspected non-Alzheimer disease pathophysiology--concept and controversy.

4. Characterization of the radiolabeled metabolite of tau PET tracer 18F-THK5351.

5. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies.

Review 6. Multimodality Review of Amyloid-related Diseases of the Central Nervous System.

Review 7. Tau immunotherapy and imaging.

Review 8. Biomarker modelling of early molecular changes in Alzheimer's disease.

9. Pharmacokinetic Evaluation of the Tau PET Radiotracer 18F-T807 (18F-AV-1451) in Human Subjects.

Review 10. Interactions between Microtubule-Associated Protein Tau (MAPT) and Small Molecules.

4. Characterization of the radiolabeled metabolite of tau PET tracer ¹⁸F-THK5351.

9. Pharmacokinetic Evaluation of the Tau PET Radiotracer ¹⁸F-T807 (¹⁸F-AV-1451) in Human Subjects.